Corporate Logo(source: tissuegene.com)
Kolon TissueGene(950160) continued its record-setting rally on November 28, rising sharply after receiving favorable assessments from securities firms.
As of 9:39 a.m., the stock was trading at 78,600 won, up 9,700 won (14.08%) from the previous session. During early trading, it climbed to 82,000 won, renewing its 52-week high once again.
Korea Investment & Securities raised its target price for Kolon TissueGene by 50% to 150,000 won while maintaining a “Buy” rating.
The brokerage cited mounting recognition among foreign investors of the potential success of TG-C — the company’s osteoarthritis treatment formerly known as Invossa.
Wi Hae-joo, analyst at Korea Investment & Securities, noted, “Kolon TissueGene’s cumulative net foreign buying in November reached 850,000 shares, suggesting that foreign investors are the first to assign higher value to the clinical and commercial potential of TG-C.”
He added, “If one factors in the likelihood of TG-C’s clinical success next year and commercialization beginning in 2028, current share price levels do not pose a burden for investors.”
Corporate Logo(source: tissuegene.com)
Kolon TissueGene(950160) continued its record-setting rally on November 28, rising sharply after receiving favorable assessments from securities firms.
As of 9:39 a.m., the stock was trading at 78,600 won, up 9,700 won (14.08%) from the previous session. During early trading, it climbed to 82,000 won, renewing its 52-week high once again.
Korea Investment & Securities raised its target price for Kolon TissueGene by 50% to 150,000 won while maintaining a “Buy” rating.
The brokerage cited mounting recognition among foreign investors of the potential success of TG-C — the company’s osteoarthritis treatment formerly known as Invossa.
Wi Hae-joo, analyst at Korea Investment & Securities, noted, “Kolon TissueGene’s cumulative net foreign buying in November reached 850,000 shares, suggesting that foreign investors are the first to assign higher value to the clinical and commercial potential of TG-C.”
He added, “If one factors in the likelihood of TG-C’s clinical success next year and commercialization beginning in 2028, current share price levels do not pose a burden for investors.”